This is also a market badly in need of new drugs: data shows ... etc.). Armed with that data, companies can more easily gauge commercial interest, determine sales margins, predict demand, and ...

In fact, companies have invested over $20 billion in research into such drugs since the 1990s. The reason why is clear: the market lifestyle ... cessation and had sales of $174m in 2000.

Amgen stock was dropping in premarket trading after releasing data from a Phase 2 study for its experimental weight-loss drug ...

The Food and Drug Administration (FDA) in the United States and European Medicines Agency (EMA) in the European Union serve as gatekeepers to the largest pharmaceutical markets worldwide, collectively ...

The antibiotics market generated sales of US$42 billion in 2009 globally, representing 46% of sales of anti-infective agents (which also include antiviral drugs and vaccines) and 5% of the global ...

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

Currently, the size of the global pharmaceutical market is around ... The increasing use of big data and artificial intelligence in researching diseases and developing new drugs massively ...

DUBLIN--(BUSINESS WIRE)--The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...

Wegovy Q3 sales total ... weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.

The global market for anti-obesity medications ... Experts predict that GLP-1 drugs could become blockbuster products with multi-billion-dollar sales potential. Eli Lilly and Novo Nordisk, too ...